ACC 2021 Presentation Adds to Body of Evidence Supporting Nuwellis Ultrafiltration to Treat Patients with Heart Failure
The study showed 83% of patients treated with Aquadex therapy experienced clinical symptom improvement (50% moderate, 33% markedly) and significant weight decrease – the mean fluid removed was 9.40L. In addition, heart failure related readmissions were significantly reduced at 60 days (p=0.017) and moderately at 90 days (p= 0.094).
Findings from this study compared favorably to several randomized controlled trials on ultrafiltration as well as the ten-year results published by
- Is effective in driving fluid removal and weight loss in ADHF patients
- Decreases heart failure readmissions
- Has no significant impact on renal function
“We saw outstanding results with Aquadex in our first year of aquapheresis ultrafiltration, which is particularly meaningful considering the disease state of the patients,” said Dr.
“Nuwellis has a strong history in the heart failure space, and this data makes it evident why,” said
About the Aquadex SmartFlow System
The Aquadex SmartFlow® system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the efficacy of Aquadex FlexFlow ultrafiltration therapy. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercial strategy, the impact of the COVID-19 pandemic, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the
Sources: 1. Costanzo MR, et al. J Am Coll Cardiol. 2017 May 16;69(19):2428-2445. 2. Watson RA, et al. Poster 155. Presented at:
Nestor JaramilloPresident, Chief Executive Officer and Chief Financial Officer, Nuwellis, Inc.email@example.com Matt Basco, CFA Gilmartin Group LLCMatt.firstname.lastname@example.org MEDIA: Laurel HoodHealth+Commerce email@example.com
Source: Nuwellis, Inc.